The Medicine Was Approved. Then the Hard Part Began.

Imagine the moment a new medicine is approved. Years of experiments, trials, regulatory questions and expensive patience have produced a yes. It feels like the finish line. Then somebody notices that doctors must understand where the treatment belongs, health systems must make room for it, patients must be able to discuss it, and internal teams must stop telling five different versions of the same story. The finish line has quietly become a starting gun.

Lucid Group occupies that awkward stretch. The London-headquartered company is not the electric-car maker whose name tends to hijack a search box. It is a healthcare communications and commercialisation consultancy founded in 2007 by Dennis O'Brien and Jan Steele. Its customers are pharmaceutical, biotech and consumer-health businesses. Its work begins with evidence and ends, when things go well, with a changed decision.

That distinction matters. Plenty of agencies can make a slide deck, convene an advisory board or build a campaign. Lucid's more interesting claim is that those are only delivery mechanisms. The actual product is movement: a clinician reconsidering a treatment pathway, a country team adopting a global programme, a patient asking a better question, or a brand team putting its budget behind the right barrier.

The first thing to fail is often the hand-off

Medicine is arranged in functions: clinical, medical, commercial, access, data, creative. Patients are not. Neither are the decisions made in a busy clinic. A strategy can therefore be perfectly sensible inside one department and strangely useless once it crosses the corridor. Lucid's answer has been to assemble scientific, behavioural, strategic, creative and analytical people around the same problem.

Its menu now runs from early asset and portfolio strategy to evidence planning, medical education, scientific storytelling, brand positioning, paid media, launch execution and lifecycle work. Lucid Connected Intelligence adds data synthesis and predictive analysis. Its AI offer is governed by published rules covering human oversight, privacy, explainability, bias and reliability. In other words, the business is designed to follow a medicine further than a traditional campaign brief usually does.

Breakthrough science doesn't commercialize itself.Bill Fay, President, Lucid Group US

The customers paying for this are not buying a mass-market product with a posted subscription price. They commission expert teams through projects and longer relationships. Lucid says its average client partnership lasts ten years, that it is a preferred partner to six of the ten largest pharmaceutical companies, and that it has helped with more than 100 launches. The names that surface publicly include AstraZeneca, Amgen and Bristol Myers Squibb; much of the rest remains anonymous, as healthcare agency work often does.

A campaign is only interesting after somebody behaves differently

Consider a first-in-class treatment entering a specialist oncology market built around surgery. The obstacle was not a lack of content. It was an existing referral habit. Lucid identified three kinds of clinical stakeholder, designed a different engagement journey for each, and connected meetings, a website and webinars around one educational narrative. Within six months, 63 percent of surveyed oncologists recognised the brand. Sales reached 168 percent of target.

In another programme, the company and clinical experts created a disease-impact tool, a treatment algorithm and a series of scientific exchanges. More than 2,000 specialists took part. Eighty-seven percent reported a shift in how they understood the disease's effect on quality of life; 92 percent of surveyed patients said the tool enabled better conversations with their doctors. These are self-reported programme outcomes, not a clinical trial. But they are more revealing than a count of brochures shipped.

The same pattern appears in smaller details. A science animation about inflammatory pathways was watched to the end by roughly 83 percent of those who pressed play and produced a 17-point increase in reported understanding. EpiCentral, an asthma education platform co-created with 14 global experts for AstraZeneca, spread into meetings, publications, social media and field activity across 23 countries, drawing more than 71,000 visits.

What it cost to build past the agency brief

The clearest public price tag belongs to Lucid itself. In 2017, private-equity firm LDC invested £11 million for a minority stake. That capital supported US expansion, digital and creative capability, and acquisitions including HealthCare21 and Bluedog. Over the next four years, reported revenue rose from £12 million to more than £29 million. In 2021, LDC sold its stake to Intermediate Capital Group for an undisclosed sum.

ICG then backed further buying. Lucid acquired life-sciences consultancy Synetic in 2023, adding operating-model, organisational and asset-planning expertise. In 2025 it combined Synetic's management-consulting work with its pharma asset strategy practice under Lucid Strategy Consulting. That same year it merged US agencies Lighthouse and DiD into Lucid Group US. The pattern is plain: acquire a missing piece, then erase the seam that the acquisition created.

By 2026, Lucid described more than 400 colleagues across four hubs. Its own breakdown is revealing: more than 100 advanced-degree specialists, 100-plus communications experts, 100-plus innovation leads and over 50 strategists. This is how the company tries to be a consultancy, a medical-communications firm and a creative agency without forcing a client to referee among three vendors.

The useful idea is not a slogan. It is an order of operations.

The part worth copying begins before anyone opens presentation software. Define the decision that needs to change. Find the friction around it. Bring the people living with that friction into the design. Only then choose the message and channel. Lucid's case studies repeatedly use co-creation with clinicians, patients, country teams and external advisers, then measure confidence, understanding, adoption or performance rather than mere exposure.

One evidence-planning assignment makes the point neatly. Internal interviews, a gap analysis and a cross-functional workshop produced a shared plan. External advisers and community representatives then challenged it. Four planned studies were modified and five new analyses commissioned. What changed the client's mind was not a louder argument. It was a better arrangement of evidence and outside voices.

There is another tension. The wider Lucid becomes, the harder it must work to preserve the closeness that made an independent agency attractive. New CEO Eric Muller arrived in August 2026 promising that senior people would remain on work from pitch through delivery. His priorities include talent, client partnerships, data and technology. The appointment of former Pfizer R&D leader Rod MacKenzie as chair a few months earlier points in the same direction: closer to the decisions that shape an asset, and further from being hired only after the strategy is set.

Lucid's wager is ultimately modest and ambitious at once. Scientific truth is necessary. It is not self-executing. Between a result in a journal and a changed life sits a human system full of doubt, habit, incentives and competing explanations. The company gets paid to make that system a little less stubborn.